Hospital Universitario Virgen de la Victoria -ko ikertzaileekin lankidetzan egindako argitalpenak (15)

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. HIV-2 and HTLV-1 infections in Spain, a non-endemic region

    AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159

  2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 8, pp. 2191-2194

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

2011

  1. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience

    Antiviral Research, Vol. 90, Núm. 3, pp. 164-167

2007

  1. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

2005

  1. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

    Clinical Infectious Diseases, Vol. 41, Núm. 2, pp. 227-232

  2. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain

    Clinical Infectious Diseases, Vol. 41, Núm. 9, pp. 1350-1354